Miguel Angel
Canales Albendea
Consultor Médico
Hospital Universitario Son Espases
Palma, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Son Espases (3)
2019
-
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966
2012
-
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series
Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819
2010
-
Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma
Blood, Vol. 116, Núm. 8